DE10399015I2 - Stabilisierte pharmazeutische formulierung, die wachstumshormon und histidin enthält - Google Patents

Stabilisierte pharmazeutische formulierung, die wachstumshormon und histidin enthält

Info

Publication number
DE10399015I2
DE10399015I2 DE10399015C DE10399015C DE10399015I2 DE 10399015 I2 DE10399015 I2 DE 10399015I2 DE 10399015 C DE10399015 C DE 10399015C DE 10399015 C DE10399015 C DE 10399015C DE 10399015 I2 DE10399015 I2 DE 10399015I2
Authority
DE
Germany
Prior art keywords
histidine
growth hormone
pharmaceutical formulation
formulation containing
containing growth
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
DE10399015C
Other languages
English (en)
Other versions
DE10399015I1 (de
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Novo Nordisk AS
Original Assignee
Novo Nordisk AS
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from DK204691A external-priority patent/DK204691D0/da
Priority claimed from DK136492A external-priority patent/DK136492D0/da
Application filed by Novo Nordisk AS filed Critical Novo Nordisk AS
Application granted granted Critical
Publication of DE10399015I2 publication Critical patent/DE10399015I2/de
Publication of DE10399015I1 publication Critical patent/DE10399015I1/de
Granted legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/22—Hormones
    • A61K38/27—Growth hormone [GH], i.e. somatotropin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/06—Drugs for disorders of the endocrine system of the anterior pituitary hormones, e.g. TSH, ACTH, FSH, LH, PRL, GH
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/575—Hormones
    • C07K14/61—Growth hormone [GH], i.e. somatotropin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Endocrinology (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Zoology (AREA)
  • Engineering & Computer Science (AREA)
  • Biochemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Biophysics (AREA)
  • Epidemiology (AREA)
  • Genetics & Genomics (AREA)
  • Toxicology (AREA)
  • Immunology (AREA)
  • Diabetes (AREA)
  • Molecular Biology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicinal Preparation (AREA)
  • Peptides Or Proteins (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
DE10399015C 1991-12-20 1992-12-16 Stabilisierte pharmazeutische formulierung, die wachstumshormon und histidin enthält Granted DE10399015I1 (de)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
DK204691A DK204691D0 (da) 1991-12-20 1991-12-20 Hidtil ukendt farmaceutisk praeparat
DK136492A DK136492D0 (da) 1992-11-10 1992-11-10 A pharmaceutical formulation
PCT/DK1992/000379 WO1993012812A1 (en) 1991-12-20 1992-12-16 A stabilized pharmaceutical formulation comprising growth hormone and histidine

Publications (2)

Publication Number Publication Date
DE10399015I2 true DE10399015I2 (de) 2008-08-07
DE10399015I1 DE10399015I1 (de) 2012-05-03

Family

ID=26065653

Family Applications (3)

Application Number Title Priority Date Filing Date
DE69232847T Expired - Lifetime DE69232847T2 (de) 1991-12-20 1992-12-16 Stabilisierte pharmazeutische formulierung, die wachstumshormon und histidin enthält
DE10399015C Granted DE10399015I1 (de) 1991-12-20 1992-12-16 Stabilisierte pharmazeutische formulierung, die wachstumshormon und histidin enthält
DE69233704T Expired - Lifetime DE69233704T2 (de) 1991-12-20 1992-12-16 Stabilisierte pharmazeutische Formulierung, umfassend Wachstumshormon und Histidin

Family Applications Before (1)

Application Number Title Priority Date Filing Date
DE69232847T Expired - Lifetime DE69232847T2 (de) 1991-12-20 1992-12-16 Stabilisierte pharmazeutische formulierung, die wachstumshormon und histidin enthält

Family Applications After (1)

Application Number Title Priority Date Filing Date
DE69233704T Expired - Lifetime DE69233704T2 (de) 1991-12-20 1992-12-16 Stabilisierte pharmazeutische Formulierung, umfassend Wachstumshormon und Histidin

Country Status (24)

Country Link
EP (2) EP0618807B1 (de)
JP (2) JP2950617B2 (de)
KR (1) KR100266502B1 (de)
AT (2) ATE227583T1 (de)
AU (1) AU667503B2 (de)
BG (1) BG63075B1 (de)
CA (1) CA2125855C (de)
CZ (1) CZ283361B6 (de)
DE (3) DE69232847T2 (de)
DK (1) DK0618807T3 (de)
ES (2) ES2185625T3 (de)
FI (1) FI115116B (de)
HU (1) HUT69402A (de)
IL (1) IL104152A (de)
MX (1) MX9207374A (de)
NL (1) NL300126I1 (de)
NO (1) NO942300L (de)
NZ (1) NZ246556A (de)
PT (1) PT618807E (de)
RO (1) RO111990B1 (de)
RU (1) RU2122426C1 (de)
SK (1) SK279641B6 (de)
UA (1) UA41502C2 (de)
WO (1) WO1993012812A1 (de)

Families Citing this family (58)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DK204791D0 (da) * 1991-12-20 1991-12-20 Novo Nordisk As Hidtil ukendt farmaceutisk praeparat
US5849704A (en) * 1991-12-20 1998-12-15 Novo Nordisk A/S Pharmaceutical formulation
US6022858A (en) * 1991-12-20 2000-02-08 Novo Nordisk A/S Pharmaceutical formulation of human-growth hormone pretreated with zinc salt
US5849700A (en) * 1991-12-20 1998-12-15 Novo Nordisk A/S Pharmaceutical formulation
US6288030B1 (en) * 1993-12-22 2001-09-11 Amgen Inc. Stem cell factor formulations and methods
DE69420872T2 (de) * 1994-06-17 2000-01-13 Applied Research Systems Hgh enthaltende pharmazeutische zubereitungen
IL114030A (en) * 1994-06-27 2000-08-13 Hayashibara Biochem Lab Saccharide composition with a lesser reducibility its preparation and compositions containing it
US5654278A (en) * 1994-10-13 1997-08-05 Novo Nordisk A/S Composition and method comprising growth hormone and leucine
US5547696A (en) * 1994-10-13 1996-08-20 Novo Nordisk A/S Pharmaceutical formulation
US5631225A (en) * 1994-10-13 1997-05-20 Novo Nordisk A/S Pharmaceutical formulation
IL115592A (en) * 1994-10-13 2000-07-26 Novo Nordisk As Stabilized pharmaceutical formulation comprising a growth hormone and leucine
EP0805689A1 (de) * 1995-01-13 1997-11-12 Novo Nordisk A/S Stabilisierte pharmazeutische zubereitung, welche ein wachstumshormon und x-lys enthält
ZA96122B (en) * 1995-01-13 1996-07-24 Novo Nordisk As A pharmaceutical formulation
US5705482A (en) * 1995-01-13 1998-01-06 Novo Nordisk A/S Pharmaceutical formulation
US5552385A (en) * 1995-06-05 1996-09-03 Novo Nordisk A/S Pharmaceutical formulation
US6936289B2 (en) 1995-06-07 2005-08-30 Danisco A/S Method of improving the properties of a flour dough, a flour dough improving composition and improved food products
ZA965367B (en) * 1995-07-12 1997-01-23 Novo Nordisk As A pharmaceutical formulation
US6267958B1 (en) 1995-07-27 2001-07-31 Genentech, Inc. Protein formulation
KR100236393B1 (ko) * 1996-02-02 1999-12-15 나까니시 히로유끼 사람성장호르몬을 함유하는 의약제제
US20070179096A1 (en) 1996-04-24 2007-08-02 Novo Nordisk A/S Pharmaceutical Formulation
US20020077461A1 (en) * 1996-04-24 2002-06-20 Soren Bjorn Pharmaceutical formulation
CA2309955A1 (en) * 1997-11-12 1999-05-20 Alza Corporation Method for decreasing self-association of polypeptides
WO1999055310A1 (en) * 1998-04-27 1999-11-04 Altus Biologics Inc. Stabilized protein crystals, formulations containing them and methods of making them
KR20090007504A (ko) 2000-02-24 2009-01-16 몬산토 테크놀로지 엘엘씨 소마토트로핀의 지속적인 방출을 위한 비수성 주사제제들
US6719992B2 (en) 2000-06-26 2004-04-13 Monsanto Technology Llc Non-aqueous surfactant-containing formulations for extended release of somatotropin
US6664234B1 (en) 2000-06-30 2003-12-16 Monsanto Technology Llc Non-aqueous injectable formulation preparation with pH adjusted for extended release of somatotropin
JP2004515467A (ja) 2000-08-07 2004-05-27 ネクター セラピューティックス 吸入可能な、噴霧乾燥した、最少の凝集物を有する４−ヘリックスバンドルタンパク質粉末
ES2477996T3 (es) 2000-08-11 2014-07-18 Chugai Seiyaku Kabushiki Kaisha Preparaciones estabilizadas que contienen un anticuerpo
DE60220155T2 (de) 2001-05-18 2008-02-07 Danisco A/S Verfahren zur herstellung von teig mit einem enzym
AU2003300126B2 (en) * 2002-12-31 2010-04-01 Altus Pharmaceuticals Inc. Complexes of protein crystals and ionic polymers
CA2512052C (en) 2002-12-31 2016-06-21 Altus Pharmaceuticals Inc. Human growth hormone crystals and methods for preparing them
AU2004261353B2 (en) 2003-08-05 2009-12-10 Novo Nordisk A/S Novel insulin derivatives
AU2005263954B2 (en) 2004-07-16 2011-04-07 Dupont Nutrition Biosciences Aps Enzymatic oil-degumming method
WO2006065861A2 (en) * 2004-12-15 2006-06-22 Amgen Inc Therapeutic formulations of keratinocyte growth factor
BRPI0519170A8 (pt) * 2004-12-22 2018-05-08 Ambrx Inc formulações de hormônio de crescimento humano que compreendem um aminoácido não naturalmente codificado
EP1928906A2 (de) * 2005-08-30 2008-06-11 Novo Nordisk Health Care AG Flüssige formulierungen von pegyliertem wachstumshormon
WO2007033427A1 (en) * 2005-09-23 2007-03-29 Metabolic Pharmaceuticals Limited Stabilisation of peptides with basic amino acids
ATE519780T1 (de) 2005-12-28 2011-08-15 Novo Nordisk As Ein acyliertes insulin und zink enthaltende zusammensetzungen und verfahren zur herstellung dieser zusammensetzungen
EP2040757A2 (de) 2006-07-07 2009-04-01 Novo Nordisk Health Care AG Neue proteinkonjugate und herstellungsverfahren
US8071544B2 (en) * 2006-12-18 2011-12-06 Althea Technologies, Inc. Crystallized recombinant human growth factor formulations
EP2167032B1 (de) 2007-06-13 2019-08-07 Novo Nordisk A/S Pharmazeutische formulierung enthaltend ein insulinderivat
CN102202683A (zh) 2008-10-30 2011-09-28 诺沃-诺迪斯克有限公司 用少于每日一次的注射频率注射胰岛素来治疗糖尿病
BR122020010601B8 (pt) * 2008-12-16 2021-07-27 Genzyme Corp conjugados de proteína-oligossacarídeo, seus usos, e composições farmacêuticas
US9238878B2 (en) 2009-02-17 2016-01-19 Redwood Bioscience, Inc. Aldehyde-tagged protein-based drug carriers and methods of use
US20120283172A1 (en) 2009-12-21 2012-11-08 Ambrx, Inc. Modified porcine somatotropin polypeptides and their uses
CN107674121A (zh) 2009-12-21 2018-02-09 Ambrx 公司 经过修饰的牛促生长素多肽和其用途
AU2011306653B2 (en) * 2010-09-21 2014-06-05 Ferring B.V. Improved process for production of recombinant human growth hormone
RU2013123515A (ru) 2010-10-27 2014-12-10 Ново Нордиск А/С Лечение сахарного диабета с помощью инъекций инсулина, вводимых с различными интервалами
KR20140016262A (ko) 2011-01-14 2014-02-07 레드우드 바이오사이언스 인코포레이티드 알데하이드-태깅된 면역글로불린 폴리펩타이드 및 이의 사용 방법
CA2875446A1 (en) 2012-06-05 2013-12-12 Neuroderm Ltd. Compositions comprising apomorphine and organic acids and uses thereof
ITBO20120368A1 (it) 2012-07-06 2014-01-07 Alfa Wassermann Spa Composizioni comprendenti rifaximina e amminoacidi, cristalli di rifaximina derivanti da tali composizioni e loro uso.
EP2991672A1 (de) 2013-04-30 2016-03-09 Novo Nordisk A/S Neuartiges verabreichungsschema
US11559580B1 (en) * 2013-09-17 2023-01-24 Blaze Bioscience, Inc. Tissue-homing peptide conjugates and methods of use thereof
AU2015416589B2 (en) * 2015-12-10 2021-04-01 Menicon Co., Ltd. Peptide composition
WO2017189432A1 (en) 2016-04-26 2017-11-02 R.P. Scherer Technologies, Llc Antibody conjugates and methods of making and using the same
US20210188941A1 (en) * 2018-05-25 2021-06-24 Dr. Reddy's Laboratories Limited Stable fusion protein formulation
US10335464B1 (en) 2018-06-26 2019-07-02 Novo Nordisk A/S Device for titrating basal insulin
WO2022197963A1 (en) * 2021-03-19 2022-09-22 Pfizer Inc. Long-acting growth hormone compositions

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4816568A (en) * 1986-05-16 1989-03-28 International Minerals & Chemical Corp. Stabilization of growth hormones
US4917685A (en) * 1986-05-16 1990-04-17 International Minerals & Chem. Corp. Delivery device for the administration of stabilized growth promoting hormones
EP0374120A3 (de) * 1988-12-13 1991-07-31 Monsanto Company Zusammensetzung mit kontrollierter Wirkstoffabgabe von Polypeptiden
DK168790D0 (de) * 1990-07-13 1990-07-13 Novo Nordisk As

Also Published As

Publication number Publication date
CA2125855A1 (en) 1993-07-08
FI942906A0 (fi) 1994-06-17
EP1197222B1 (de) 2007-08-01
EP1197222A3 (de) 2004-02-04
SK279641B6 (sk) 1999-01-11
CZ283361B6 (cs) 1998-03-18
NZ246556A (en) 1996-03-26
DE69233704D1 (de) 2007-09-13
RU2122426C1 (ru) 1998-11-27
DE69233704T2 (de) 2008-05-21
AU667503B2 (en) 1996-03-28
JPH11315031A (ja) 1999-11-16
NO942300D0 (no) 1994-06-17
DE10399015I1 (de) 2012-05-03
IL104152A0 (en) 1993-05-13
FI942906A (fi) 1994-06-17
SK75494A3 (en) 1995-03-08
NL300126I1 (nl) 2003-07-01
ES2185625T3 (es) 2003-05-01
PT618807E (pt) 2003-03-31
JPH07502516A (ja) 1995-03-16
NO942300L (no) 1994-08-19
IL104152A (en) 1998-06-15
EP0618807B1 (de) 2002-11-13
BG63075B1 (bg) 2001-03-30
ATE368472T1 (de) 2007-08-15
HUT69402A (en) 1995-09-28
HU9401832D0 (en) 1994-09-28
DK0618807T3 (da) 2003-03-03
CZ150794A3 (en) 1995-01-18
FI115116B (fi) 2005-03-15
KR100266502B1 (ko) 2000-09-15
ES2291264T3 (es) 2008-03-01
ATE227583T1 (de) 2002-11-15
JP2950617B2 (ja) 1999-09-20
MX9207374A (es) 1993-07-01
WO1993012812A1 (en) 1993-07-08
EP1197222A2 (de) 2002-04-17
RO111990B1 (ro) 1997-04-30
EP0618807A1 (de) 1994-10-12
AU3344693A (en) 1993-07-28
DE69232847D1 (de) 2002-12-19
CA2125855C (en) 2008-05-13
BG98806A (bg) 1995-02-28
RU94045932A (ru) 1997-04-20
DE69232847T2 (de) 2003-09-11
UA41502C2 (uk) 2001-09-17

Similar Documents

Publication Publication Date Title
ATE227583T1 (de) Stabilisierte pharmazeutische formulierung, die wachstumshormon und histidin enthält
DE69228704T2 (de) Stabilisierte pharmazeutische formulierung, die wachstumshormon und asparagin enthält
ES2173197T3 (es) Una formula farmaceutica que contiene hormona de crecimiento e isoleucina.
DE69524965D1 (de) Wachstumshormon und valin enthaltende arzneimittel
IL115592A (en) Stabilized pharmaceutical formulation comprising a growth hormone and leucine
HUP9802286A2 (hu) Stabilizált gyógyszerkészítmény amely valamely növekedési hormont és legalább egy bázikus aminosavmaradékot és legalább egy savas aminosav maradékot tartalmazó peptidet foglal magában